Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial - Brown, J P; Roux, C; Torring, O (J Bone Miner Res, 2013)
et al.